Moderna has entered into a development and commercialization funding agreement with asset management firm Blackstone Life Sciences to help advance its pipeline of flu vaccine candidates.
Tag Archive for: commercialization
The new offering will help life science and pharmaceutical brands create better and more personalized experiences for both diagnosed and undiagnosed patient populations, accelerating paths to diagnosis and treatment, and creating unmatched educational opportunities. Brand teams will gain unmatched insights into what patient communities are saying and looking for, and then serve up customized content to help them at any stage of the patient journey.
Market access emerged as a crucial commercial function at pharmaceutical manufacturers a little over 20 years ago, followed closely by the creation of specialized market access agencies. With so much changing over the last two decades, the time is right to take a fresh look at how market access agencies support manufacturers today to ensure that expectations are aligned and that unrealized potential doesn’t negatively impact brands.
The suite of capabilities combines deep market and patient insights, launch strategy expertise, and rigorous cross-functional execution to ensure relentless alignment throughout the product launch process.
This first-to-market technology gives patient service teams nearly immediate insight into patient coverage from both pharmacy and major medical plans, the potential need for prior authorization support, and any financial responsibilities impacting patient access and speed to treatment.
Urhekar will play a key role on the company’s Executive Committee as he unites 1,600 employees as one team under a single vision, breaking down barriers to faster-connect patients to life-enhancing therapies. All business units — Consulting; Medical; Policy; Value, Evidence and Access; Marketing; and Digital Experience and Technology — will report to Urhekar.
Market access in oncology impacts HCP willingness to write the Rx, ability for the office staff to facilitate clearance of the prior authorizations to access the Rx, and patient affordability to start and stay on therapy over time. Particularly for patients and caregivers who are told they must enter battle with the diagnosis of a solid or squamous tumor type — avoiding delays to the initiation of therapy is vital to helping improve the chances of survival with a meaningful quality of life.
Polymath marketer Ryan Mason leads the newly expanded group, and Jeffrey D. Erb has been tapped to grow the media and analytics team as Chief Media Officer.
The partnership supports commitment to providing high-quality products, supply chain continuity, and exceptional customer service.
The agreement is the culmination of a comprehensive review of opportunities available to Syneos Health, including interest from multiple parties with the assistance of independent financial and legal advisors.
